A ROS‐Responsive Dual‐Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T‐Cell Acute Lymphoblastic Leukemia
Open Access
- 31 May 2025
- journal article
- Published by Wiley in Advanced Science
- Vol. 12 (31) , e05087
Abstract
T‐cell acute lymphoblastic leukemia (T‐ALL) is a highly aggressive hematological malignancy for which targeted therapies remain underdeveloped. Oncogenic mutations in Notch1 occur in up to 75% of T‐ALL patients. Although γ‐secretase inhibitors (GSIs) can block Notch1 activation, their clinical application is limited by side effects and reduced sensitivity. Here, a self‐assembling, reactive oxygen species (ROS)‐responsive nanotherapeutic strategy—PHD/G‐NPs—co‐loaded with GSI and controlled released dihydroartemisinin (DHA), and modified with a CD38 antibody is reported. The CD38 antibody specifically targets T‐ALL cells, while GSI selectively inhibits Notch1, resulting in a dual‐targeting approach. GSI is released first, inhibiting Notch1 activation and inducing the death of a subset of T‐ALL cells. To eliminate semi‐quiescent T‐ALL cells that escape initial therapy by elevating ROS levels, a ROS‐sensitive DHA delivery system is employed to enhance ferroptosis and boost GSI efficacy. After elucidating the mechanism of action of PHD/G‐NPs in T‐ALL cells, PHD/G‐NPs are combined with αPD‐1, which triggers an anti‐tumor immune response in vivo. This dual‐targeting strategy using CD38‐modified PHD/G‐NPs enables controlled drug release, enhances ferroptosis, mitigates GSI‐induced gastrointestinal toxicity, and improves therapeutic efficacy. This nanomedical approach offers a novel strategy for targeted T‐ALL treatment.Keywords
Funding Information
- National Natural Science Foundation of China (82070160, 82170182, 82370165, 82470153, 82470163, 82473859)
- Natural Science Foundation of Shandong Province (ZR2023MH228, ZR2023YQ065, ZR2024QH600, ZR202111140029)
- China Postdoctoral Science Foundation (2023M742111)
- Fundamental Research Funds for the Central Universities (2022JC012)
This publication has 36 references indexed in Scilit:
- Blocking Ubiquitin‐Specific Protease 7 Induces Ferroptosis in Gastric Cancer via Targeting Stearoyl‐CoA DesaturaseAdvanced Science, 2024
- Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategyCell Metabolism, 2022
- DT7 peptide-modified lecithin nanoparticles co-loaded with γ-secretase inhibitor and dexamethasone efficiently inhibit T-cell acute lymphoblastic leukemia and reduce gastrointestinal toxicityCancer Letters, 2022
- Hyaluronic acid - dihydroartemisinin conjugate: Synthesis, characterization and in vitro evaluation in lung cancer cellsInternational Journal of Biological Macromolecules, 2019
- DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritinFree Radical Biology and Medicine, 2019
- Comparison of in vitro/in vivo blood distribution and pharmacokinetics of artemisinin, artemether and dihydroartemisinin in ratsJournal of Pharmaceutical and Biomedical Analysis, 2019
- Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisininEuropean Journal of Medicinal Chemistry, 2017
- Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cellsApoptosis, 2015
- Targeting Notch signaling pathway in cancer: Clinical development advances and challengesPharmacology & Therapeutics, 2014
- The role of aldehyde dehydrogenase (ALDH) in cancer drug resistanceBiomedicine & Pharmacotherapy, 2013